Livagen
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
Livagen is a Khavinson tetrapeptide for the liver — part of the digestive/hepatic corner of the Khavinson short-peptide bioregulator family, alongside Pancragen and Ovagen.
What does it do in my body?
Claimed mechanism: promotes chromatin decondensation in hepatocytes, reactivating silenced genes — consistent with the family’s chromatin-remodeling in-vitro line (Khavinson, Lezhava, Malinin 2004, Bull Exp Biol Med, 15085253). That study is family-wide mechanism evidence, not a Livagen-specific trial.
How can it help me?
- Where the science stands: Site tier Anecdotal (0 studies cited specifically for Livagen)
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
No adverse-event data exists for Livagen. The family-wide reported profile in the Russian literature is mild and uncommon: occasional injection-site reactions, transient mild headache early in a cycle.
The real risk isn’t the molecule — it’s the supply chain. Khavinson-family peptides are the dominant gray-market counterfeit category in the peptide space, and Livagen’s thin published record makes it an easy target for mislabeling. Third-party COA verification matters more here than for almost any other peptide class.
Regulatory status: Livagen is research_only in the US — not FDA-approved for human use, sold as a research compound, not eligible for compounding. It is not a controlled substance.
Typical dosing
Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.
Educational purposes only — this reflects the Khavinson-school protocol convention shared across the family; it is not medical advice.
There is no dosing or cycling data specific to Livagen — the evidence base is zero studies. What exists is only the generic Khavinson-family cycle pattern: a short course of 10–20 days, repeated 2–3 times per year, with synthetic short peptides in the family generally dosed around ~100–200 mcg/day — but none of this has been validated for Livagen specifically.
What should I avoid combining — and what's synergistic?
Livagen doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
How can I buy this?
Livagen is available from BioLongevity Labs — use code OHM-15 at BioLongevity for 15% off. As always, buy only from a source that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity.
When you use my coupon code to buy peptides with these sellers, you enjoy a discount off retail price, and I make a small commission which helps me to continue to offer this peptide educational site to you for free. I only have affiliate relationships with peptide manufacturers that show evidence that their peptides are 100% manufactured in the US, 3rd party lab tested for purity, transparent COAs posted on their websites, and that have good customer service.
Livagen (Lys-Glu-Asp-Ala / KEDA) is a Khavinson tetrapeptide for the liver. The evidence base is thin — zero studies cited specifically for Livagen — so this article stays short and honest rather than padding it with the family’s general chromatin-mechanism work.
| Class | Khavinson tetrapeptide — Lys-Glu-Asp-Ala (KEDA) |
| Mechanism (one line) | Claimed to promote chromatin decondensation in hepatocytes, reactivating silenced genes |
| Evidence base | Site tier Anecdotal (0 studies cited specifically for Livagen) |
| Safety record | No AE data specific to Livagen; family-wide mild profile assumed; OHM grade D / provisional |
| Regulatory status | research_only in the US, not FDA-approved |
What it is
Livagen is a Khavinson tetrapeptide for the liver — part of the digestive/hepatic corner of the Khavinson short-peptide bioregulator family, alongside Pancragen and Ovagen.
How it works
Claimed mechanism: promotes chromatin decondensation in hepatocytes, reactivating silenced genes — consistent with the family’s chromatin-remodeling in-vitro line (Khavinson, Lezhava, Malinin 2004, Bull Exp Biol Med, 15085253). That study is family-wide mechanism evidence, not a Livagen-specific trial.
What the research shows
Site tier is Anecdotal (0 studies cited for Livagen specifically). There is no Livagen-specific human or animal data. OHM grade: D / provisional.
Real-world protocol
Educational purposes only — this reflects the Khavinson-school protocol convention shared across the family; it is not medical advice.
There is no dosing or cycling data specific to Livagen — the evidence base is zero studies. What exists is only the generic Khavinson-family cycle pattern: a short course of 10–20 days, repeated 2–3 times per year, with synthetic short peptides in the family generally dosed around ~100–200 mcg/day — but none of this has been validated for Livagen specifically.
Side effects & management
No adverse-event data exists for Livagen. The family-wide reported profile in the Russian literature is mild and uncommon: occasional injection-site reactions, transient mild headache early in a cycle.
The real risk isn’t the molecule — it’s the supply chain. Khavinson-family peptides are the dominant gray-market counterfeit category in the peptide space, and Livagen’s thin published record makes it an easy target for mislabeling. Third-party COA verification matters more here than for almost any other peptide class.
Regulatory status
Livagen is research_only in the US — not FDA-approved for human use, sold as a research compound, not eligible for compounding. It is not a controlled substance.
Sources
- primary profile (thepeptidelist.com directory capture, 2026-06-07).
- 0035 tier/safety/goal grading: Livagen kept D-provisional / encyclopedia-only.
- Family-mechanism 15085253 (Khavinson/Lezhava/Malinin 2004).
- Related: Pancragen · Ovagen · the Khavinson bioregulator family.
Sources & references
- primary profile (thepeptidelist.com directory capture, 2026-06-07).
- 0035 tier/safety/goal grading: Livagen kept D-provisional / encyclopedia-only.
- Family-mechanism 15085253 (Khavinson/Lezhava/Malinin 2004).
- Related: Pancragen · Ovagen · the Khavinson bioregulator family.